Maria Afrazi

机构：Arrowhead Pharmaceuticals (United States)

发表论文 7 篇 · 总被引 77 次 · h-index 3

代表论文

• Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD (2024 · New England Journal of Medicine · 被引 65)
• Silencing MMP7 expression with a lung-targeted RNAi molecule limits fibrosis and preserves pulmonary function in bleomycin-injured rats (2022 · 12.01 - Idiopathic interstitial pneumonias · 被引 6)
• A clinical-stage RNAi therapeutic candidate for IPF mediates durable MMP7 silencing in nonhuman primates and human lung tissue (2023 · 被引 3)
• Rage Silencing Via Inhaled Epithelium Targeted Sirna Mitigates Neutrophilic Inflammation in Rat Models of COPD and ARDS (2025 · American Journal of Respiratory and Critical Care Medicine · 被引 1)
• Lung-targeted RNAi Molecules Silence Human TSLP Expression in PCLS Cultures and Humanized Mice and Suppress Pulmonary Allergic Inflammation (2024 · 被引 1)
• Silencing TSLP expression with a lung-targeted RNAi molecule suppresses pulmonary allergic inflammation (2023 · 被引 1)